Although not immediately practice-changing, impressive results from the NICHE-2 trial may open a way to a ‘watch and wait’ approach for some patients

Disease-free and overall survival in the PRODIGE-24/CCTG PA6 study were significantly higher in GemPred-positive versus GemPred-negative patients who received adjuvant gemcitabine

Two early studies investigate the anticancer activity of derazantinib and RLY-4008 in patients with FGFR inhibitor-naïve cholangiocarcinoma  

Updated overall survival data from TOPAZ-1 confirm clinically meaningful benefit of adding durvalumab to cisplatin/gemcitabine 

Standard second-line chemotherapy may benefit fit patients but efficacy is limited and new treatments are urgently needed

Encouraging efficacy data with anti-PD1 antibody in combination or as monotherapy

Thanks to remarkable advances, molecular analysis has taken central stage in the management of GIST, but there is still a need for less costly testing and further development of mitigation strategies to overcome resistance

The COSMIC-312 trial met its primary endpoint of progression-free survival, but interim overall survival results need further exploration 

Risk assessment and alternative fluoropyrimidine regimens are the main changes in the Pan-Asian adapted ESMO Clinical Practice Guidelines, reinforcing ESMO’s commitment in the region 

Knock-on effects of early immune checkpoint inhibitor use stimulate consideration of alternative approaches for further treatment lines